Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-GD2 immunotherapy

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 7, 2003, Pages 515-519

  Kushner, Brian H ^a   Kramer, Kim ^a   LaQuaglia, Michael P ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunotherapy; Neuroblastoma; Nonstage 4 disease; Relapse

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GD2 MONOCLONAL ANTIBODY 3F8; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISOTRETINOIN; MOLECULAR MARKER; MONOCLONAL ANTIBODY 3F8 I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHEILITIS; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEARING IMPAIRMENT; HUMAN; HYPOTHYROIDISM; INFANT; MALE; MUCOSA INFLAMMATION; NEUROBLASTOMA; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; RECURRENT CANCER; URTICARIA;

CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; IMMUNOTHERAPY; INFANT; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 0037634528     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200307000-00003     Document Type: Article

References (39)

1. Castleberry RP. Neuroblastoma. Eur J Cancer. 1997;33:1430-1438.
2. Matthay KK, Stram D. Is adjuvant therapy ever warranted in localized neuroblastoma? J Pediatr Hematol/Oncol. 2000;22:399-404.
3. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
4. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery. A Pediatric Oncology Group study. J Clin Oncol. 1988;6:1271-1279.
5. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989;7:236-244.
6. Evans AE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies. A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996;14:2405-2410.
7. Cheung N-KV, Kushner BH, LaQuaglia MP, et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy. An analysis of clinical and biologic markers. Eur J Cancer. 1997;33:2117-2120.
8. Cheung N-KV, Kushner BH, LaQuaglia M, et al. N7. A novel multi-modality therapy of high-risk neuroblastoma in children diagnosed over 1 year of age. Med Pediatr Oncol. 2000;36:227-230.
9. D2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189-4194.
10. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994;12:2607-2613.
11. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose (21 Gy) radiotherapy for high-risk neuroblastoma following intensive chemotherapy and surgery. J Clin Oncol. 2001;19:2821-2828.
12. D2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053-3060.
13. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
14. Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma. A Children's Cancer Group study. J Clin Oncol. 2000;18:4067-4076.
15. Yeh SDJ, Burch L, LaQuaglia MP, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8. Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991;932:769-776.
16. Nitschke R, Smith EI, Altshuler G, et al. Postoperative treatment of nonmetastatic visible residual neuroblastoma. A Pediatric Oncology Group study. J Clin Oncol. 1991;9:1181-1188.
17. Castleberry RP, Shuster JJ, Altshuler G, et al. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy. A Pediatric Oncology Group study. J Clin Oncol. 1992;10:1299-1304.
18. Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favorable neuroblastoma based on the degree of initial tumor resection. Results from the Pediatric Oncology Group. Eur J Cancer. 1997;33:2121-2125.
19. Alvarado CS, London WB, Look T, et al. Natural history and biology of stage A neuroblastoma. A Pediatric Oncology Group study. J Pediatr Hemat/Oncol. 2000;22:197-205.
20. Evans AR, Brand W, de Lorimier A, et al. Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazole-carboxamide. A report from the Children's Cancer Study Group. Am J Clin Oncol. 1984;6:3-8.
21. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging. A Children's Cancer Group study. J Clin Oncol. 1998;16:1256-1264.
22. Perez CA, Matthay KK, Atkinson JB, et al. Biological variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy. A Children's Cancer Group study. J Clin Oncol. 2000;18:18-26.
23. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma. Results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1995;13:884-893.
24. Rubie H, Hartman O, Michon J, et al. N-myc gene amplification is a major prognostic factor in localized neuroblastoma. Results of the French NBL 90 Study. J Clin Oncol. 1997;15:1171-1182.
25. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998;16:1265-1269.
26. Woods WG, Ru-Nie G, Shuster J, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041-1046.
27. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047-1053.
28. Berthold F, Hero B, Breu H, et al. The recurrence patterns of stage I, II, and III neuroblastoma. Experience with 77 relapsing patients. Ann Oncol. 1996;7:183-187.
29. Ayukawa H, Umemoto Y, Kawasaki K, et al. Myeloid-positive T cell acute leukemia after treatment of infantile neuroblastoma. Med Pediatr Oncol. 2001;37:479-480.
30. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma. A prospective Children's Cancer Group study. J Clin Oncol. 2000;18:1260-1268.
31. 131I-metaiodo-benzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16:229-236.
32. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142-2149.
33. Yu A, Uttenreuther-Fischer MM, Huang C-S, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-2180.
34. D2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation. A Children's Cancer Group study. J Clin Oncol. 2000;18:4077-4085.
35. Blatt J, Gula MJ, Orlando SJ, et al. Indolent course of advanced neuroblastoma in children older than 6 years at diagnosis. Cancer. 1995;76:890-894.
36. Bourhis J, DeVathaire F, Wilson GD, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 1991;51:33-36.
37. Muraji T, Okamoto E, Fujimoto J, et al. Combined determination of N-myc oncogene amplification and DNA ploidy in neuroblastoma. Cancer. 1993;72:2763-2768.
38. Ladenstein R, Ambros IM, Potschger U, et al. The prognostic significance of DNA di/tetraploidy in neuroblastoma [abstract]. Med Pediatr Oncol. 1998;31:189.
39. Maris JM, Weiss MJ, Gui C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients. A Children's Cancer Group study. J Clin Oncol. 2000;18:1888-1899.